All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Visual abstract | CEPHEUS: Updated minimal residual disease analysis

By Devon Moss

Share:

Nov 16, 2026

Learning objective: After reading this article, learners will be able to discuss the benefit of adding daratumumab to bortezomib, lenalidomide, and dexamethasone on sustained MRD negativity in patients with NDMM.


Do you know... Which of the following regarding sustained MRD negativity was observed in patients with NDMM after 6 years of follow-up in the CEPHEUS trial?

Improved depth of response and progression-free survival (PFS) with daratumumab + bortezomib + lenalidomide + dexamethasone (DVRd) vs bortezomib + lenalidomide + dexamethasone (VRd) has previously been demonstrated in patients with newly diagnosed multiple myeloma (NDMM) who were transplant-ineligible or transplant-deferred in the phase III CEPHEUS trial. This final analysis, with a median follow-up of 76 months, evaluated the depth, durability, and clinical relevance of minimal residual disease (MRD) negativity achieved with DVRd.

Here, we present a visual abstract summarizing key findings from data presented at the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK.

Enlarge 

This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Visual abstract

To download this visual abstract, click below.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.